-DOCSTART- -X- O
Virus-like -X- _ B-Intervention
particles -X- _ I-Intervention
( -X- _ I-Intervention
VLPs -X- _ I-Intervention
) -X- _ I-Intervention
present -X- _ O
viral -X- _ O
antigens -X- _ O
in -X- _ O
a -X- _ O
native -X- _ O
conformation -X- _ O
and -X- _ O
are -X- _ O
effectively -X- _ O
recognized -X- _ O
by -X- _ O
the -X- _ O
immune -X- _ O
system -X- _ O
and -X- _ O
therefore -X- _ O
are -X- _ O
considered -X- _ O
as -X- _ O
suitable -X- _ O
and -X- _ O
safe -X- _ O
vaccine -X- _ O
candidates -X- _ O
against -X- _ O
many -X- _ O
viral -X- _ O
diseases. -X- _ O
Here -X- _ O
we -X- _ O
demonstrate -X- _ O
that -X- _ O
chimeric -X- _ B-Intervention
VLPs -X- _ I-Intervention
containing -X- _ I-Intervention
Rift -X- _ I-Intervention
Valley -X- _ I-Intervention
fever -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
RVFV -X- _ I-Intervention
) -X- _ I-Intervention
glycoproteins -X- _ I-Intervention
G -X- _ I-Intervention
( -X- _ I-Intervention
N -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
G -X- _ I-Intervention
( -X- _ I-Intervention
C -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
nucleoprotein -X- _ I-Intervention
N -X- _ I-Intervention
and -X- _ I-Intervention
the -X- _ I-Intervention
gag -X- _ I-Intervention
protein -X- _ I-Intervention
of -X- _ I-Intervention
Moloney -X- _ I-Intervention
murine -X- _ I-Intervention
leukemia -X- _ I-Intervention
virus -X- _ I-Intervention
represent -X- _ O
an -X- _ O
effective -X- _ O
vaccine -X- _ O
candidate -X- _ O
against -X- _ O
Rift -X- _ B-Patient
Valley -X- _ I-Patient
fever -X- _ I-Patient
, -X- _ O
a -X- _ O
deadly -X- _ O
disease -X- _ O
in -X- _ O
humans -X- _ O
and -X- _ O
livestock. -X- _ O
Long-lasting -X- _ B-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
are -X- _ I-Outcome
demonstrated -X- _ I-Outcome
in -X- _ O
a -X- _ O
mouse -X- _ O
model -X- _ O
by -X- _ O
the -X- _ O
analysis -X- _ O
of -X- _ O
neutralizing -X- _ O
antibody -X- _ O
titers -X- _ O
and -X- _ O
cytokine -X- _ O
secretion -X- _ O
profiles. -X- _ O
Vaccine -X- _ O
efficacy -X- _ O
studies -X- _ O
were -X- _ O
performed -X- _ O
in -X- _ O
mouse -X- _ B-Patient
and -X- _ I-Patient
rat -X- _ I-Patient
lethal -X- _ O
challenge -X- _ O
models -X- _ O
resulting -X- _ O
in -X- _ O
high -X- _ O
protection -X- _ O
rates. -X- _ O
Taken -X- _ O
together -X- _ O
, -X- _ O
these -X- _ O
results -X- _ O
demonstrate -X- _ O
that -X- _ O
replication-incompetent -X- _ B-Outcome
chimeric -X- _ I-Outcome
RVF -X- _ I-Outcome
VLPs -X- _ I-Outcome
are -X- _ I-Outcome
an -X- _ I-Outcome
efficient -X- _ I-Outcome
RVFV -X- _ I-Outcome
vaccine -X- _ I-Outcome
candidate -X- _ I-Outcome
. -X- _ O

